Hormone replacement therapy: who should be treated?

Area of Science:

• Reproductive Endocrinology
• Women's Health
• Menopause Management

Background:

• The last decade saw extensive re-evaluation of hormone replacement therapy (HRT) risks and benefits.
• Different HRT formulations and dosages present varied advantages for distinct female populations.

Purpose of the Study:

• To review the current evidence on the benefits and risks of hormone replacement therapy (HRT).
• To identify specific patient groups and menopausal stages where HRT is most advantageous.
• To assess the safety profile of different HRT doses and combinations.

Main Methods:

• Review of existing literature and clinical evidence on hormone replacement therapy (HRT).
• Analysis of HRT efficacy and safety data across different age groups and menopausal statuses.
• Evaluation of HRT's impact on menopausal symptoms, cardiovascular disease (CVD), osteoporosis, and mortality.

Main Results:

• HRT is beneficial for women with premature or early menopause until the typical age of natural menopause.
• Symptomatic women aged 50-59 within 10 years of menopause show significant benefits, including reduced CVD, fractures, and mortality.
• Low-dose or ultra-low-dose HRT may offer a better safety profile in older women compared to standard doses.

Conclusions:

• HRT can be advantageous for younger women experiencing premature or early menopause.
• The most significant benefits of HRT are observed in symptomatic women within 10 years of menopause.
• Current evidence does not support using HRT solely for preventing osteoporosis, cardiovascular disease, or cognitive decline.